Stay updated with the latest liposome news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on liposome topics.
New Delhi: What if doctors could tell, right at the time of breast cancer diagnosis, which patient is more likely to face heart problems years later? A new study in JAMA Oncology suggests that may soon be possible.The study, which followed more than 26,000 women with early-stage breast cancer, developed a risk prediction model that can identify those most likely to develop heart failure or cardiomyopathy -- two serious long-term complications of cancer treatment. Researchers found that the model ...Read More >
Bengaluru: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Doxil Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL), of Baxter Health ...Read More >
New Delhi, Jun 30 (PTI) Alembic Pharmaceuticals on Monday said it has received the final approval from the US health regulator for its generic Doxorubicin Hydrochloride Liposome injection in different types of cancer. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) is for Doxorubicin Hydrochloride Liposome injection of strengths 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials, Alembic Pharmaceuticals said in a statement ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.